FDA Hands Boston Scientific Warning Letter For Clinical Trial Violations
This article was originally published in The Gray Sheet
Executive Summary
A recent bioresearch monitoring 1warning letter to Boston Scientific, sent Aug. 30, is unrelated to an outstanding corporate-wide letter issued to the firm in 2006 - but the two letters, taken together, could make life harder for the company